Zepbound is an injectable prescription medication created to help adults with obesity and weight-related problems, including obstructive sleep apnea. OSA causes airway collapses during sleep and ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Medicare drug plans can now cover Eli Lilly's blockbuster obesity drug Zepbound for obstructive sleep apnea, the Centers for Medicare & Medicaid Services confirmed to CNBC. That opens the door for ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

The U.S. Food and Drug Administration approved Zepbound for patients with obesity and mild to moderate obstructive sleep apnea on Dec. 20, making it the first approved treatment for the roughly 20 ...